Global Multiple Sclerosis Drugs Market Growth 2025-2031

October 2025 | 96 pages | ID: GF66BC96B183EN
LP Information

Abstracts

The global Multiple Sclerosis Drugs market size is predicted to grow from US$ 16930 million in 2025 to US$ 22940 million in 2031; it is expected to grow at a CAGR of 5.2% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the ?Multiple Sclerosis Drugs Industry Forecast? looks at past sales and reviews total world Multiple Sclerosis Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Multiple Sclerosis Drugs sales for 2025 through 2031. With Multiple Sclerosis Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Multiple Sclerosis Drugs industry.

This Insight Report provides a comprehensive analysis of the global Multiple Sclerosis Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Multiple Sclerosis Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Multiple Sclerosis Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Multiple Sclerosis Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Multiple Sclerosis Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Multiple Sclerosis Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Injectable Medications
• Oral Medications
• Others

Segmentation by Application:

• Adults
• Children

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Biogen
• Sanofi
• Novartis
• Teva
• Merck KGaA
• Bayer
• ACORDA
• Mallinckrodt

Key Questions Addressed in this Report

What is the 10-year outlook for the global Multiple Sclerosis Drugs market?
What factors are driving Multiple Sclerosis Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Multiple Sclerosis Drugs market opportunities vary by end market size?
How does Multiple Sclerosis Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Multiple Sclerosis Drugs Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Multiple Sclerosis Drugs by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Multiple Sclerosis Drugs by Country/Region, 2020, 2024 & 2031
2.2 Multiple Sclerosis Drugs Segment by Type
  2.2.1 Injectable Medications
  2.2.2 Oral Medications
  2.2.3 Others
2.3 Multiple Sclerosis Drugs Sales by Type
  2.3.1 Global Multiple Sclerosis Drugs Sales Market Share by Type (2020-2025)
  2.3.2 Global Multiple Sclerosis Drugs Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Multiple Sclerosis Drugs Sale Price by Type (2020-2025)
2.4 Multiple Sclerosis Drugs Segment by Application
  2.4.1 Adults
  2.4.2 Children
2.5 Multiple Sclerosis Drugs Sales by Application
  2.5.1 Global Multiple Sclerosis Drugs Sale Market Share by Application (2020-2025)
  2.5.2 Global Multiple Sclerosis Drugs Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Multiple Sclerosis Drugs Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Multiple Sclerosis Drugs Breakdown Data by Company
  3.1.1 Global Multiple Sclerosis Drugs Annual Sales by Company (2020-2025)
  3.1.2 Global Multiple Sclerosis Drugs Sales Market Share by Company (2020-2025)
3.2 Global Multiple Sclerosis Drugs Annual Revenue by Company (2020-2025)
  3.2.1 Global Multiple Sclerosis Drugs Revenue by Company (2020-2025)
  3.2.2 Global Multiple Sclerosis Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Multiple Sclerosis Drugs Sale Price by Company
3.4 Key Manufacturers Multiple Sclerosis Drugs Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Multiple Sclerosis Drugs Product Location Distribution
  3.4.2 Players Multiple Sclerosis Drugs Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR MULTIPLE SCLEROSIS DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Multiple Sclerosis Drugs Market Size by Geographic Region (2020-2025)
  4.1.1 Global Multiple Sclerosis Drugs Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Multiple Sclerosis Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Multiple Sclerosis Drugs Market Size by Country/Region (2020-2025)
  4.2.1 Global Multiple Sclerosis Drugs Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Multiple Sclerosis Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Multiple Sclerosis Drugs Sales Growth
4.4 APAC Multiple Sclerosis Drugs Sales Growth
4.5 Europe Multiple Sclerosis Drugs Sales Growth
4.6 Middle East & Africa Multiple Sclerosis Drugs Sales Growth

5 AMERICAS

5.1 Americas Multiple Sclerosis Drugs Sales by Country
  5.1.1 Americas Multiple Sclerosis Drugs Sales by Country (2020-2025)
  5.1.2 Americas Multiple Sclerosis Drugs Revenue by Country (2020-2025)
5.2 Americas Multiple Sclerosis Drugs Sales by Type (2020-2025)
5.3 Americas Multiple Sclerosis Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Multiple Sclerosis Drugs Sales by Region
  6.1.1 APAC Multiple Sclerosis Drugs Sales by Region (2020-2025)
  6.1.2 APAC Multiple Sclerosis Drugs Revenue by Region (2020-2025)
6.2 APAC Multiple Sclerosis Drugs Sales by Type (2020-2025)
6.3 APAC Multiple Sclerosis Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Multiple Sclerosis Drugs by Country
  7.1.1 Europe Multiple Sclerosis Drugs Sales by Country (2020-2025)
  7.1.2 Europe Multiple Sclerosis Drugs Revenue by Country (2020-2025)
7.2 Europe Multiple Sclerosis Drugs Sales by Type (2020-2025)
7.3 Europe Multiple Sclerosis Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Multiple Sclerosis Drugs by Country
  8.1.1 Middle East & Africa Multiple Sclerosis Drugs Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Multiple Sclerosis Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Multiple Sclerosis Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Multiple Sclerosis Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Multiple Sclerosis Drugs
10.3 Manufacturing Process Analysis of Multiple Sclerosis Drugs
10.4 Industry Chain Structure of Multiple Sclerosis Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Multiple Sclerosis Drugs Distributors
11.3 Multiple Sclerosis Drugs Customer

12 WORLD FORECAST REVIEW FOR MULTIPLE SCLEROSIS DRUGS BY GEOGRAPHIC REGION

12.1 Global Multiple Sclerosis Drugs Market Size Forecast by Region
  12.1.1 Global Multiple Sclerosis Drugs Forecast by Region (2026-2031)
  12.1.2 Global Multiple Sclerosis Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Multiple Sclerosis Drugs Forecast by Type (2026-2031)
12.7 Global Multiple Sclerosis Drugs Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Biogen
  13.1.1 Biogen Company Information
  13.1.2 Biogen Multiple Sclerosis Drugs Product Portfolios and Specifications
  13.1.3 Biogen Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Biogen Main Business Overview
  13.1.5 Biogen Latest Developments
13.2 Sanofi
  13.2.1 Sanofi Company Information
  13.2.2 Sanofi Multiple Sclerosis Drugs Product Portfolios and Specifications
  13.2.3 Sanofi Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Sanofi Main Business Overview
  13.2.5 Sanofi Latest Developments
13.3 Novartis
  13.3.1 Novartis Company Information
  13.3.2 Novartis Multiple Sclerosis Drugs Product Portfolios and Specifications
  13.3.3 Novartis Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Novartis Main Business Overview
  13.3.5 Novartis Latest Developments
13.4 Teva
  13.4.1 Teva Company Information
  13.4.2 Teva Multiple Sclerosis Drugs Product Portfolios and Specifications
  13.4.3 Teva Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Teva Main Business Overview
  13.4.5 Teva Latest Developments
13.5 Merck KGaA
  13.5.1 Merck KGaA Company Information
  13.5.2 Merck KGaA Multiple Sclerosis Drugs Product Portfolios and Specifications
  13.5.3 Merck KGaA Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Merck KGaA Main Business Overview
  13.5.5 Merck KGaA Latest Developments
13.6 Bayer
  13.6.1 Bayer Company Information
  13.6.2 Bayer Multiple Sclerosis Drugs Product Portfolios and Specifications
  13.6.3 Bayer Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Bayer Main Business Overview
  13.6.5 Bayer Latest Developments
13.7 ACORDA
  13.7.1 ACORDA Company Information
  13.7.2 ACORDA Multiple Sclerosis Drugs Product Portfolios and Specifications
  13.7.3 ACORDA Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 ACORDA Main Business Overview
  13.7.5 ACORDA Latest Developments
13.8 Mallinckrodt
  13.8.1 Mallinckrodt Company Information
  13.8.2 Mallinckrodt Multiple Sclerosis Drugs Product Portfolios and Specifications
  13.8.3 Mallinckrodt Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 Mallinckrodt Main Business Overview
  13.8.5 Mallinckrodt Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Multiple Sclerosis Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Multiple Sclerosis Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Injectable Medications
Table 4. Major Players of Oral Medications
Table 5. Major Players of Others
Table 6. Global Multiple Sclerosis Drugs Sales by Type (2020-2025) & (K Units)
Table 7. Global Multiple Sclerosis Drugs Sales Market Share by Type (2020-2025)
Table 8. Global Multiple Sclerosis Drugs Revenue by Type (2020-2025) & ($ million)
Table 9. Global Multiple Sclerosis Drugs Revenue Market Share by Type (2020-2025)
Table 10. Global Multiple Sclerosis Drugs Sale Price by Type (2020-2025) & (USD/Unit)
Table 11. Global Multiple Sclerosis Drugs Sale by Application (2020-2025) & (K Units)
Table 12. Global Multiple Sclerosis Drugs Sale Market Share by Application (2020-2025)
Table 13. Global Multiple Sclerosis Drugs Revenue by Application (2020-2025) & ($ million)
Table 14. Global Multiple Sclerosis Drugs Revenue Market Share by Application (2020-2025)
Table 15. Global Multiple Sclerosis Drugs Sale Price by Application (2020-2025) & (USD/Unit)
Table 16. Global Multiple Sclerosis Drugs Sales by Company (2020-2025) & (K Units)
Table 17. Global Multiple Sclerosis Drugs Sales Market Share by Company (2020-2025)
Table 18. Global Multiple Sclerosis Drugs Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Multiple Sclerosis Drugs Revenue Market Share by Company (2020-2025)
Table 20. Global Multiple Sclerosis Drugs Sale Price by Company (2020-2025) & (USD/Unit)
Table 21. Key Manufacturers Multiple Sclerosis Drugs Producing Area Distribution and Sales Area
Table 22. Players Multiple Sclerosis Drugs Products Offered
Table 23. Multiple Sclerosis Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Multiple Sclerosis Drugs Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Multiple Sclerosis Drugs Sales Market Share Geographic Region (2020-2025)
Table 28. Global Multiple Sclerosis Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Multiple Sclerosis Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Multiple Sclerosis Drugs Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Multiple Sclerosis Drugs Sales Market Share by Country/Region (2020-2025)
Table 32. Global Multiple Sclerosis Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Multiple Sclerosis Drugs Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Multiple Sclerosis Drugs Sales by Country (2020-2025) & (K Units)
Table 35. Americas Multiple Sclerosis Drugs Sales Market Share by Country (2020-2025)
Table 36. Americas Multiple Sclerosis Drugs Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Multiple Sclerosis Drugs Sales by Type (2020-2025) & (K Units)
Table 38. Americas Multiple Sclerosis Drugs Sales by Application (2020-2025) & (K Units)
Table 39. APAC Multiple Sclerosis Drugs Sales by Region (2020-2025) & (K Units)
Table 40. APAC Multiple Sclerosis Drugs Sales Market Share by Region (2020-2025)
Table 41. APAC Multiple Sclerosis Drugs Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Multiple Sclerosis Drugs Sales by Type (2020-2025) & (K Units)
Table 43. APAC Multiple Sclerosis Drugs Sales by Application (2020-2025) & (K Units)
Table 44. Europe Multiple Sclerosis Drugs Sales by Country (2020-2025) & (K Units)
Table 45. Europe Multiple Sclerosis Drugs Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Multiple Sclerosis Drugs Sales by Type (2020-2025) & (K Units)
Table 47. Europe Multiple Sclerosis Drugs Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Multiple Sclerosis Drugs Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Multiple Sclerosis Drugs Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Multiple Sclerosis Drugs Sales by Type (2020-2025) & (K Units)
Table 51. Middle East & Africa Multiple Sclerosis Drugs Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Multiple Sclerosis Drugs
Table 53. Key Market Challenges & Risks of Multiple Sclerosis Drugs
Table 54. Key Industry Trends of Multiple Sclerosis Drugs
Table 55. Multiple Sclerosis Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Multiple Sclerosis Drugs Distributors List
Table 58. Multiple Sclerosis Drugs Customer List
Table 59. Global Multiple Sclerosis Drugs Sales Forecast by Region (2026-2031) & (K Units)
Table 60. Global Multiple Sclerosis Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Multiple Sclerosis Drugs Sales Forecast by Country (2026-2031) & (K Units)
Table 62. Americas Multiple Sclerosis Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Multiple Sclerosis Drugs Sales Forecast by Region (2026-2031) & (K Units)
Table 64. APAC Multiple Sclerosis Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Multiple Sclerosis Drugs Sales Forecast by Country (2026-2031) & (K Units)
Table 66. Europe Multiple Sclerosis Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Multiple Sclerosis Drugs Sales Forecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Multiple Sclerosis Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Multiple Sclerosis Drugs Sales Forecast by Type (2026-2031) & (K Units)
Table 70. Global Multiple Sclerosis Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Multiple Sclerosis Drugs Sales Forecast by Application (2026-2031) & (K Units)
Table 72. Global Multiple Sclerosis Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Biogen Basic Information, Multiple Sclerosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. Biogen Multiple Sclerosis Drugs Product Portfolios and Specifications
Table 75. Biogen Multiple Sclerosis Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. Biogen Main Business
Table 77. Biogen Latest Developments
Table 78. Sanofi Basic Information, Multiple Sclerosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Sanofi Multiple Sclerosis Drugs Product Portfolios and Specifications
Table 80. Sanofi Multiple Sclerosis Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Sanofi Main Business
Table 82. Sanofi Latest Developments
Table 83. Novartis Basic Information, Multiple Sclerosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Novartis Multiple Sclerosis Drugs Product Portfolios and Specifications
Table 85. Novartis Multiple Sclerosis Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. Novartis Main Business
Table 87. Novartis Latest Developments
Table 88. Teva Basic Information, Multiple Sclerosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Teva Multiple Sclerosis Drugs Product Portfolios and Specifications
Table 90. Teva Multiple Sclerosis Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. Teva Main Business
Table 92. Teva Latest Developments
Table 93. Merck KGaA Basic Information, Multiple Sclerosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Merck KGaA Multiple Sclerosis Drugs Product Portfolios and Specifications
Table 95. Merck KGaA Multiple Sclerosis Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Merck KGaA Main Business
Table 97. Merck KGaA Latest Developments
Table 98. Bayer Basic Information, Multiple Sclerosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Bayer Multiple Sclerosis Drugs Product Portfolios and Specifications
Table 100. Bayer Multiple Sclerosis Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 101. Bayer Main Business
Table 102. Bayer Latest Developments
Table 103. ACORDA Basic Information, Multiple Sclerosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. ACORDA Multiple Sclerosis Drugs Product Portfolios and Specifications
Table 105. ACORDA Multiple Sclerosis Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 106. ACORDA Main Business
Table 107. ACORDA Latest Developments
Table 108. Mallinckrodt Basic Information, Multiple Sclerosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Mallinckrodt Multiple Sclerosis Drugs Product Portfolios and Specifications
Table 110. Mallinckrodt Multiple Sclerosis Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 111. Mallinckrodt Main Business
Table 112. Mallinckrodt Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Multiple Sclerosis Drugs
Figure 2. Multiple Sclerosis Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Multiple Sclerosis Drugs Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Multiple Sclerosis Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Multiple Sclerosis Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Multiple Sclerosis Drugs Sales Market Share by Country/Region (2024)
Figure 10. Multiple Sclerosis Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Injectable Medications
Figure 12. Product Picture of Oral Medications
Figure 13. Product Picture of Others
Figure 14. Global Multiple Sclerosis Drugs Sales Market Share by Type in 2025
Figure 15. Global Multiple Sclerosis Drugs Revenue Market Share by Type (2020-2025)
Figure 16. Multiple Sclerosis Drugs Consumed in Adults
Figure 17. Global Multiple Sclerosis Drugs Market: Adults (2020-2025) & (K Units)
Figure 18. Multiple Sclerosis Drugs Consumed in Children
Figure 19. Global Multiple Sclerosis Drugs Market: Children (2020-2025) & (K Units)
Figure 20. Global Multiple Sclerosis Drugs Sale Market Share by Application (2024)
Figure 21. Global Multiple Sclerosis Drugs Revenue Market Share by Application in 2025
Figure 22. Multiple Sclerosis Drugs Sales by Company in 2025 (K Units)
Figure 23. Global Multiple Sclerosis Drugs Sales Market Share by Company in 2025
Figure 24. Multiple Sclerosis Drugs Revenue by Company in 2025 ($ millions)
Figure 25. Global Multiple Sclerosis Drugs Revenue Market Share by Company in 2025
Figure 26. Global Multiple Sclerosis Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 27. Global Multiple Sclerosis Drugs Revenue Market Share by Geographic Region in 2025
Figure 28. Americas Multiple Sclerosis Drugs Sales 2020-2025 (K Units)
Figure 29. Americas Multiple Sclerosis Drugs Revenue 2020-2025 ($ millions)
Figure 30. APAC Multiple Sclerosis Drugs Sales 2020-2025 (K Units)
Figure 31. APAC Multiple Sclerosis Drugs Revenue 2020-2025 ($ millions)
Figure 32. Europe Multiple Sclerosis Drugs Sales 2020-2025 (K Units)
Figure 33. Europe Multiple Sclerosis Drugs Revenue 2020-2025 ($ millions)
Figure 34. Middle East & Africa Multiple Sclerosis Drugs Sales 2020-2025 (K Units)
Figure 35. Middle East & Africa Multiple Sclerosis Drugs Revenue 2020-2025 ($ millions)
Figure 36. Americas Multiple Sclerosis Drugs Sales Market Share by Country in 2025
Figure 37. Americas Multiple Sclerosis Drugs Revenue Market Share by Country (2020-2025)
Figure 38. Americas Multiple Sclerosis Drugs Sales Market Share by Type (2020-2025)
Figure 39. Americas Multiple Sclerosis Drugs Sales Market Share by Application (2020-2025)
Figure 40. United States Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 41. Canada Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 42. Mexico Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 43. Brazil Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 44. APAC Multiple Sclerosis Drugs Sales Market Share by Region in 2025
Figure 45. APAC Multiple Sclerosis Drugs Revenue Market Share by Region (2020-2025)
Figure 46. APAC Multiple Sclerosis Drugs Sales Market Share by Type (2020-2025)
Figure 47. APAC Multiple Sclerosis Drugs Sales Market Share by Application (2020-2025)
Figure 48. China Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 49. Japan Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 50. South Korea Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 51. Southeast Asia Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. India Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. Australia Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. China Taiwan Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. Europe Multiple Sclerosis Drugs Sales Market Share by Country in 2025
Figure 56. Europe Multiple Sclerosis Drugs Revenue Market Share by Country (2020-2025)
Figure 57. Europe Multiple Sclerosis Drugs Sales Market Share by Type (2020-2025)
Figure 58. Europe Multiple Sclerosis Drugs Sales Market Share by Application (2020-2025)
Figure 59. Germany Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 60. France Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 61. UK Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 62. Italy Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. Russia Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. Middle East & Africa Multiple Sclerosis Drugs Sales Market Share by Country (2020-2025)
Figure 65. Middle East & Africa Multiple Sclerosis Drugs Sales Market Share by Type (2020-2025)
Figure 66. Middle East & Africa Multiple Sclerosis Drugs Sales Market Share by Application (2020-2025)
Figure 67. Egypt Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 68. South Africa Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 69. Israel Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 70. Turkey Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. GCC Countries Multiple Sclerosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. Manufacturing Cost Structure Analysis of Multiple Sclerosis Drugs in 2025
Figure 73. Manufacturing Process Analysis of Multiple Sclerosis Drugs
Figure 74. Industry Chain Structure of Multiple Sclerosis Drugs
Figure 75. Channels of Distribution
Figure 76. Global Multiple Sclerosis Drugs Sales Market Forecast by Region (2026-2031)
Figure 77. Global Multiple Sclerosis Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 78. Global Multiple Sclerosis Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 79. Global Multiple Sclerosis Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 80. Global Multiple Sclerosis Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 81. Global Multiple Sclerosis Drugs Revenue Market Share Forecast by Application (2026-2031)